It is demonstrated that AMP effectively mitigates SAMW by activating AMPK and suppressing IL-1β-mediated molecular pathways and highlighting the potential of AMP as a novel therapeutic agent for preserving skeletal muscle functionality and morphology in sepsis.
Abstract
Sepsis-associated muscle wasting (SAMW) causes long-term functional decline, even after recovery. Emerging evidence indicates that adenosine 5'-monophosphate (AMP) confers organ-protective effects in response to physiological stress or injury, potentially through the activation of AMP-activated protein kinase (AMPK) signalling pathways. In this study, we investigated the effects of AMP on SAMW to evaluate its efficacy as a therapeutic agent to alleviate SAMW. In vivo, a mouse model of cecum ligation and puncture sepsis was established using male C57BL/6 mice, which received intraperitoneal AMP (0.5 mg/g) or saline as a control. In vitro, C2C12 myoblasts and RAW264.7 macrophages were cultured under standard conditions and treated with AMP. Forelimb grip strength, blood and muscle sampling, western blotting, AMP assays, RNA sequencing, ELISA, flow cytometry, real-time PCR, immunohistochemistry, histology, and computed tomography imaging were performed to assess molecular, cellular, and physiological responses. In addition, plasma samples from patients with sepsis were analysed to explore translational relevance. AMP suppressed sepsis-induced inflammatory cytokine production and improved muscle strength by attenuating mammalian target of rapamycin complex 1 activation and modulating AMPK signaling, thereby contributing to the preservation of muscle mass and a reduction in systemic inflammation. In vitro, AMP suppressed LPS- induced IL-1β production in RAW264.7 macrophages and attenuated LPS- or IL-1β-induced myotube atrophy in C2C12 cells and shifted the cells towards a fast-twitch phenotype. Evaluation of clinical samples revealed elevated inflammatory cytokines in patients with sepsis exhibiting muscle wasting. This study demonstrates that AMP effectively mitigates SAMW by activating AMPK and suppressing IL-1β-mediated molecular pathways. These findings highlight the potential of AMP as a novel therapeutic agent for preserving skeletal muscle functionality and morphology in sepsis.
Findings reveal a previously unrecognized epigenetic mechanism underlying sepsis-induced inflammation and identify the EP300/ATF4/H4K5-hib positive feedback loop as a potential therapeutic target for sepsis.
Liang Zhang, Yong-Ling Lu, Hongmei Qiu et al.· British Journal of Pharmacol...· 0 citations
It is concluded that Luteolin contains anti-inflammatory and anti-oxidative properties; it has cardioprotective benefits and demonstrated a cardioprotective impact by influencing the AMPK-Nrf2 genes' tissue mRNA expression.
Haider W. Alaa, F. A. Ghafil, Sahar A. Majeed et al.· Journal of Phytomedicine and...· 0 citations
Results demonstrated that PD intervention markedly reduced protein degradation mediated by the ubiquitin-proteasome system and attenuated sepsis-induced muscle atrophy, highlighting its potential as a protective strategy against this clinical condition.
Yingfang Zheng, Hongkai Dai, Ting-ting Xu et al.· International Immunopharmaco...· 0 citations
Findings support a hepatocyte-centered immunometabolic model in which Dex treatment is associated with α2-AR-dependent HPD regulation, altered hepatic HIF-1α levels, reduced neutrophil oxidative burst and NET formation, and attenuation of Th17 polarization and organ injury in sepsis.
Hai-Hong Fang, Shuang Wang, Zhuo Ma et al.· Archives of pharmacal resear...· 0 citations
FGF21 overexpression alleviates sepsis-associated myocardial injury by restoring mitochondrial function via AMPK/PGC-1α pathway by restoring mitochondrial function via AMPK/PGC-1α pathway.
Li-Ping Mao, D. Dang, Wenjing Wang· Biochemical and Biophysical...· 0 citations